PDF herunterladen
Semin Liver Dis 2019; 39(03): 301-314
DOI: 10.1055/s-0039-1685518
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Hepatitis B Virus–Hepatocyte Interactions and Innate Immune Responses: Experimental Models and Molecular Mechanisms

Emmanuel Thomas
1   Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida
2   Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida
3   Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida
,
Thomas F. Baumert
4   Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France
5   Laboratory of Excellence HEPSYS, University of Strasbourg, Strasbourg, France
6   Institut Hospitalo-Universitaire, Pôle hépato-digestif, Nouvel Hôpital Civil, Strasbourg, France
› Institutsangaben Funding E.T. acknowledges support from the NIH (R35GM124915) and Florida Department of Health Bankhead-Coley Cancer Research Program (7BC03). T.F.B. acknowledges support from the European Union (ERC-AdG-HEPCIR, ERC-PoC-2016-PRELICAN, and EU H2020-667273-HEPCAR) ARC, Paris and Institut Hospitalo-Universitaire, Strasbourg (TheraHCC IHUARC IHU201301187), U Strasbourg Foundation HEPKIN, the National Institutes of Health (NCI 1R21CA209940-01A1, NIAID R03AI131066, and NIAID 5U19AI123862-02), and the Institut Universitaire de France (IUF). This work has been published under the framework of the LABEX ANR-10-LABX-0028_HEPSYS and benefits from funding from the state managed by the French National Research Agency as part of the Investments for the Future Program.
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
02. Juli 2019 (online)

    Lizenzen und Reprints

Abstract

Chronic hepatitis B virus (HBV) infection is a major cause of liver disease and cancer worldwide. While current therapeutic approaches can efficiently control viral infection, efficient curative antivirals are absent. The understanding of virus–hepatocyte interactions and sensing of viral infection is an important prerequisite for the development of novel antiviral therapies for cure. Hepatocyte intrinsic innate immunity provides a rapid first line of defense to combat viral infection through the upregulation of antiviral and inflammatory genes. However, the functional relevance of many of these antiviral signaling pathways in the liver and their role in HBV pathogenesis is still only partially understood. The recent identification of intracellular RNA and DNA sensing pathways and their involvement in disease biology, including viral pathogenesis and carcinogenesis, is currently transforming our understanding of virus–host interactions. Here the authors review the current knowledge on intrinsic antiviral innate immune responses including the role of viral nucleic acid sensing pathways in the liver. Since HBV has been designated as a “stealth virus,” the study of the impact of HBV on signaling pathways in the hepatocyte is of significant interest to understand viral pathogenesis. Characterizing the mechanism underlying these HBV–host interactions and targeting related pathways to enhance antiviral innate responses may open new strategies to trigger noncytopathic clearance of covalently closed circular DNA to ultimately cure patients with chronic HBV infection.

Keywords

hepatitis b virus - chemokines - cytokines - antiviral immune responses - IRF3 - nuclear factor-kappaB - pattern recognition receptor - host defense - intrinsic innate responses

Author Contributions

Paper concept, design, and drafting of the manuscript by E.T. and T.F.B.


 

  • References

  • 1 McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49 (5, Suppl): S45-S55
    CrossrefPubMedGoogle Scholar
  • 2 Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 2014; 28 (05) 753-770
    CrossrefPubMedGoogle Scholar
  • 3 Burns GS, Thompson AJ. Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med 2014; 4 (12) a024935
    CrossrefPubMedGoogle Scholar
  • 4 Tsai KN, Kuo CF, Ou JJ. Mechanisms of hepatitis B virus persistence. Trends Microbiol 2018; 26 (01) 33-42
    CrossrefPubMedGoogle Scholar
  • 5 Gehring AJ. New treatments to reach functional cure: rationale and challenges for emerging immune-based therapies. Best Pract Res Clin Gastroenterol 2017; 31 (03) 337-345
    CrossrefPubMedGoogle Scholar
  • 6 Chang J, Block TM, Guo JT. The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res 2012; 96 (03) 405-413
    CrossrefPubMedGoogle Scholar
  • 7 Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J 2013; 10: 239
    CrossrefPubMedGoogle Scholar
  • 8 Lamb C, Arbuthnot P. Activating the innate immune response to counter chronic hepatitis B virus infection. Expert Opin Biol Ther 2016; 16 (12) 1517-1527
    CrossrefPubMedGoogle Scholar
  • 9 Gao B, Jeong WI, Tian Z. Liver: an organ with predominant innate immunity. Hepatology 2008; 47 (02) 729-736
    PubMedGoogle Scholar
  • 10 Thomas E, Gonzalez VD, Li Q. , et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142 (04) 978-988
    CrossrefPubMedGoogle Scholar
  • 11 Rosen HR. Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest 2013; 123 (10) 4121-4130
    CrossrefPubMedGoogle Scholar
  • 12 Shoukry NH. Hepatitis C vaccines, antibodies, and T cells. Front Immunol 2018; 9: 1480
    CrossrefPubMedGoogle Scholar
  • 13 Testoni B, Durantel D, Zoulim F. Novel targets for hepatitis B virus therapy. Liver Int 2017; 37 (Suppl. 01) 33-39
    CrossrefPubMedGoogle Scholar
  • 14 Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology 2015; 479-480: 672-686
    PubMedGoogle Scholar
  • 15 Faure-Dupuy S, Lucifora J, Durantel D. Interplay between the hepatitis B virus and innate immunity: from an understanding to the development of therapeutic concepts. Viruses 2017; 9 (05) E95
    CrossrefPubMedGoogle Scholar
  • 16 Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009; 21 (04) 317-337
    CrossrefPubMedGoogle Scholar
  • 17 Sato S, Li K, Kameyama T. , et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity 2015; 42 (01) 123-132
    CrossrefPubMedGoogle Scholar
  • 18 Foy E, Li K, Sumpter Jr R. , et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A 2005; 102 (08) 2986-2991
    CrossrefPubMedGoogle Scholar
  • 19 Li K, Chen Z, Kato N, Gale Jr M, Lemon SM. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem 2005; 280 (17) 16739-16747
    CrossrefPubMedGoogle Scholar
  • 20 Sumpter Jr R, Loo YM, Foy E. , et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005; 79 (05) 2689-2699
    CrossrefPubMedGoogle Scholar
  • 21 Wang N, Liang Y, Devaraj S, Wang J, Lemon SM, Li K. Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J Virol 2009; 83 (19) 9824-9834
    CrossrefPubMedGoogle Scholar
  • 22 Sun Q, Wang Q, Scott MJ, Billiar TR. Immune activation in the liver by nucleic acids. J Clin Transl Hepatol 2016; 4 (02) 151-157
    PubMedGoogle Scholar
  • 23 Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008; 455 (7213): 674-678
    CrossrefPubMedGoogle Scholar
  • 24 Ishii KJ, Coban C, Kato H. , et al. A toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 2006; 7 (01) 40-48
    CrossrefPubMedGoogle Scholar
  • 25 Chiu YH, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 2009; 138 (03) 576-591
    CrossrefPubMedGoogle Scholar
  • 26 Verrier ER, Yim SA, Heydmann L. , et al. Hepatitis B virus evasion from cyclic guanosine monophosphate-adenosine monophosphate synthase sensing in human hepatocytes. Hepatology 2018; 68 (05) 1695-1709
    CrossrefPubMedGoogle Scholar
  • 27 Cheng X, Xia Y, Serti E. , et al. Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages. Hepatology 2017; 66 (06) 1779-1793
    CrossrefPubMedGoogle Scholar
  • 28 Yoneda M, Hyun J, Jakubski S. , et al. Hepatitis B virus and DNA stimulation trigger a rapid innate immune response through NF-κB. J Immunol 2016; 197 (02) 630-643
    CrossrefPubMedGoogle Scholar
  • 29 Thomsen MK, Nandakumar R, Stadler D. , et al. Lack of immunological DNA sensing in hepatocytes facilitates hepatitis B virus infection. Hepatology 2016; 64 (03) 746-759
    CrossrefPubMedGoogle Scholar
  • 30 Rall LB, Standring DN, Laub O, Rutter WJ. Transcription of hepatitis B virus by RNA polymerase II. Mol Cell Biol 1983; 3 (10) 1766-1773
    CrossrefPubMedGoogle Scholar
  • 31 Standring DN, Rall LB, Laub O, Rutter WJ. Hepatitis B virus encodes an RNA polymerase III transcript. Mol Cell Biol 1983; 3 (10) 1774-1782
    CrossrefPubMedGoogle Scholar
  • 32 Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, Zaaijer HL. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues. J Infect Dis 2016; 213 (02) 224-232
    CrossrefPubMedGoogle Scholar
  • 33 Galle PR, Hagelstein J, Kommerell B, Volkmann M, Schranz P, Zentgraf H. In vitro experimental infection of primary human hepatocytes with hepatitis B virus. Gastroenterology 1994; 106 (03) 664-673
    CrossrefPubMedGoogle Scholar
  • 34 Seeger C, Zoulim F, Mason WS. Hepadnaviruses. In: Knipe DM, Howley PM. , eds. Field Virology. 5th ed., Vol. 2. Philadelphia, PA: Lippincott Williams & Wilkins; 2007: 2977-3027
    Google Scholar
  • 35 Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004; 101 (17) 6669-6674
    CrossrefPubMedGoogle Scholar
  • 36 Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 2005; 79 (15) 9369-9380
    CrossrefPubMedGoogle Scholar
  • 37 Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284 (5415): 825-829
    CrossrefPubMedGoogle Scholar
  • 38 Stacey AR, Norris PJ, Qin L. , et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83 (08) 3719-3733
    CrossrefPubMedGoogle Scholar
  • 39 Dunn C, Peppa D, Khanna P. , et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009; 137 (04) 1289-1300
    CrossrefPubMedGoogle Scholar
  • 40 Tan AT, Koh S, Goh W. , et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol 2010; 52 (03) 330-339
    CrossrefPubMedGoogle Scholar
  • 41 Luangsay S, Ait-Goughoulte M, Michelet M. , et al. Expression and functionality of Toll- and RIG-like receptors in HepaRG cells. J Hepatol 2015; 63 (05) 1077-1085
    CrossrefPubMedGoogle Scholar
  • 42 Giersch K, Allweiss L, Volz T. , et al. Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection. J Hepatol 2015; 63 (02) 346-353
    CrossrefPubMedGoogle Scholar
  • 43 Papatheodoridis G, Goulis J, Manolakopoulos S. , et al. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy. J Hepatol 2014; 60 (01) 62-68
    CrossrefPubMedGoogle Scholar
  • 44 Luangsay S, Gruffaz M, Isorce N. , et al. Early inhibition of hepatocyte innate responses by hepatitis B virus. J Hepatol 2015; 63 (06) 1314-1322
    CrossrefPubMedGoogle Scholar
  • 45 Bauer T, Sprinzl M, Protzer U. Immune control of hepatitis B virus. Dig Dis 2011; 29 (04) 423-433
    CrossrefPubMedGoogle Scholar
  • 46 Villeneuve JP. The natural history of chronic hepatitis B virus infection. J Clin Virol 2005; 34 (Suppl. 01) S139-S142
    CrossrefPubMedGoogle Scholar
  • 47 Verrier ER, Colpitts CC, Schuster C, Zeisel MB, Baumert TF. Cell culture models for the investigation of hepatitis B and D virus infection. Viruses 2016; 8 (09) E261
    CrossrefPubMedGoogle Scholar
  • 48 Thomas E, Liang TJ. Experimental models of hepatitis B and C – new insights and progress. Nat Rev Gastroenterol Hepatol 2016; 13 (06) 362-374
    CrossrefPubMedGoogle Scholar
  • 49 Naik S, Russell SJ. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther 2009; 9 (09) 1163-1176
    CrossrefPubMedGoogle Scholar
  • 50 Keskinen P, Nyqvist M, Sareneva T, Pirhonen J, Melén K, Julkunen I. Impaired antiviral response in human hepatoma cells. Virology 1999; 263 (02) 364-375
    CrossrefPubMedGoogle Scholar
  • 51 Melén K, Keskinen P, Lehtonen A, Julkunen I. Interferon-induced gene expression and signaling in human hepatoma cell lines. J Hepatol 2000; 33 (05) 764-772
    CrossrefPubMedGoogle Scholar
  • 52 Israelow B, Narbus CM, Sourisseau M, Evans MJ. HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection. Hepatology 2014; 60 (04) 1170-1179
    CrossrefPubMedGoogle Scholar
  • 53 Naka K, Dansako H, Kobayashi N, Ikeda M, Kato N. Hepatitis C virus NS5B delays cell cycle progression by inducing interferon-beta via toll-like receptor 3 signaling pathway without replicating viral genomes. Virology 2006; 346 (02) 348-362
    CrossrefPubMedGoogle Scholar
  • 54 Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z. Hepatitis B virus polymerase inhibits RIG-I- and toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 2010; 91 (Pt 8): 2080-2090
    CrossrefPubMedGoogle Scholar
  • 55 Bility MT, Cheng L, Zhang Z. , et al. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. PLoS Pathog 2014; 10 (03) e1004032
    CrossrefPubMedGoogle Scholar
  • 56 Gripon P, Rumin S, Urban S. , et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002; 99 (24) 15655-15660
    CrossrefPubMedGoogle Scholar
  • 57 Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 2007; 168 (01) 66-73
    CrossrefPubMedGoogle Scholar
  • 58 Andersson TB, Kanebratt KP, Kenna JG. The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human. Expert Opin Drug Metab Toxicol 2012; 8 (07) 909-920
    CrossrefPubMedGoogle Scholar
  • 59 Michailidis E, Pabon J, Xiang K. , et al. A robust cell culture system supporting the complete life cycle of hepatitis B virus. Sci Rep 2017; 7 (01) 16616
    CrossrefPubMedGoogle Scholar
  • 60 Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 2007; 46 (06) 1759-1768
    CrossrefPubMedGoogle Scholar
  • 61 Tu T, Budzinska MA, Vondran FWR, Shackel NA, Urban S. Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via NTCP-dependent uptake of enveloped virus particles. J Virol 2018; JVI.02007-17
    PubMedGoogle Scholar
  • 62 Li MMH, MacDonald MR, Rice CM. To translate, or not to translate: viral and host mRNA regulation by interferon-stimulated genes. Trends Cell Biol 2015; 25 (06) 320-329
    CrossrefPubMedGoogle Scholar
  • 63 Schoggins JW, Wilson SJ, Panis M. , et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011; 472 (7344): 481-485
    PubMedGoogle Scholar
  • 64 Andrus L, Marukian S, Jones CT. , et al. Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Hepatology 2011; 54 (06) 1901-1912
    CrossrefPubMedGoogle Scholar
  • 65 Hyun I. Policy: Regulate embryos made for research. Nature 2014; 509 (7498): 27-28
    PubMedGoogle Scholar
  • 66 Elaut G, Henkens T, Papeleu P. , et al. Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Curr Drug Metab 2006; 7 (06) 629-660
    CrossrefPubMedGoogle Scholar
  • 67 Rijntjes PJM, Moshage HJ, Yap SH. In vitro infection of primary cultures of cryopreserved adult human hepatocytes with hepatitis B virus. Virus Res 1988; 10 (01) 95-109
    CrossrefPubMedGoogle Scholar
  • 68 Gripon P, Diot C, Thézé N. , et al. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol 1988; 62 (11) 4136-4143
    CrossrefPubMedGoogle Scholar
  • 69 Ochiya T, Tsurimoto T, Ueda K, Okubo K, Shiozawa M, Matsubara K. An in vitro system for infection with hepatitis B virus that uses primary human fetal hepatocytes. Proc Natl Acad Sci U S A 1989; 86 (06) 1875-1879
    CrossrefPubMedGoogle Scholar
  • 70 Shlomai A, Schwartz RE, Ramanan V. , et al. Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. Proc Natl Acad Sci U S A 2014; 111 (33) 12193-12198
    CrossrefPubMedGoogle Scholar
  • 71 Wu X, Robotham JM, Lee E. , et al. Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog 2012; 8 (04) e1002617
    CrossrefPubMedGoogle Scholar
  • 72 Gómez-Lechón MJ, Donato MT, Castell JV, Jover R. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metab 2004; 5 (05) 443-462
    CrossrefPubMedGoogle Scholar
  • 73 Sheahan T, Imanaka N, Marukian S. , et al. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 2014; 15 (02) 190-202
    CrossrefPubMedGoogle Scholar
  • 74 Schwartz RE, Shan J, Duncan SA, Goessling W, Bhatia S. Engineering the microenvironment of differentiating IPS derived hepatocyte-like cells enables acquisition of an adult phenotype. Gastroenterology 2013; 144 (05) S1025
    PubMedGoogle Scholar
  • 75 Shan J, Schwartz RE, Ross NT. , et al. Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat Chem Biol 2013; 9 (08) 514-520
    CrossrefPubMedGoogle Scholar
  • 76 Asumda FZ, Hatzistergos KE, Dykxhoorn DM. , et al. Differentiation of hepatocyte-like cells from human pluripotent stem cells using small molecules. Differentiation 2018; 101: 16-24
    CrossrefPubMedGoogle Scholar
  • 77 Zhang L, Dailey PJ, Gettie A, Blanchard J, Ho DD. The liver is a major organ for clearing simian immunodeficiency virus in rhesus monkeys. J Virol 2002; 76 (10) 5271-5273
    CrossrefPubMedGoogle Scholar
  • 78 He XS, Nanda S, Ji X, Calderon-Rodriguez GM, Greenberg HB, Liang TJ. Differential transcriptional responses to interferon-alpha and interferon-gamma in primary human hepatocytes. J Interferon Cytokine Res 2010; 30 (05) 311-320
    CrossrefPubMedGoogle Scholar
  • 79 Nakamoto N, Kanai T. Role of toll-like receptors in immune activation and tolerance in the liver. Front Immunol 2014; 5: 221
    PubMedGoogle Scholar
  • 80 Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17 (01) 1-14
    PubMedGoogle Scholar
  • 81 Pei RJ, Chen XW, Lu MJ. Control of hepatitis B virus replication by interferons and toll-like receptor signaling pathways. World J Gastroenterol 2014; 20 (33) 11618-11629
    CrossrefPubMedGoogle Scholar
  • 82 Zhang E, Lu M. Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol (Berl) 2015; 204 (01) 11-20
    CrossrefPubMedGoogle Scholar
  • 83 Kumar H, Kawai T, Akira S. Pathogen recognition in the innate immune response. Biochem J 2009; 420 (01) 1-16
    CrossrefPubMedGoogle Scholar
  • 84 Gao D, Wu J, Wu YT. , et al. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 2013; 341 (6148): 903-906
    CrossrefPubMedGoogle Scholar
  • 85 Schoggins JW, MacDuff DA, Imanaka N. , et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 2014; 505 (7485): 691-695
    PubMedGoogle Scholar
  • 86 Cui X, Clark DN, Liu K, Xu XD, Guo JT, Hu J. Viral DNA-dependent induction of innate immune response to hepatitis B virus in immortalized mouse hepatocytes. J Virol 2015; 90 (01) 486-496
    PubMedGoogle Scholar
  • 87 Dansako H, Ueda Y, Okumura N. , et al. The cyclic GMP-AMP synthetase-STING signaling pathway is required for both the innate immune response against HBV and the suppression of HBV assembly. FEBS J 2016; 283 (01) 144-156
    CrossrefPubMedGoogle Scholar
  • 88 Guo F, Han Y, Zhao X. , et al. STING agonists induce an innate antiviral immune response against hepatitis B virus. Antimicrob Agents Chemother 2015; 59 (02) 1273-1281
    CrossrefPubMedGoogle Scholar
  • 89 Paludan SR, Bowie AG. Immune sensing of DNA. Immunity 2013; 38 (05) 870-880
    CrossrefPubMedGoogle Scholar
  • 90 Zhang X, Shi H, Wu J. , et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell 2013; 51 (02) 226-235
    CrossrefPubMedGoogle Scholar
  • 91 Dempsey A, Bowie AG. Innate immune recognition of DNA: a recent history. Virology 2015; 479–480: 146-152
    PubMedGoogle Scholar
  • 92 Bürckstümmer T, Baumann C, Blüml S. , et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009; 10 (03) 266-272
    CrossrefPubMedGoogle Scholar
  • 93 Chen J, Wu M, Zhang X. , et al. Hepatitis B virus polymerase impairs interferon-α-induced STA T activation through inhibition of importin-α5 and protein kinase C-δ. Hepatology 2013; 57 (02) 470-482
    CrossrefPubMedGoogle Scholar
  • 94 Mutz P, Metz P, Lempp FA. , et al. HBV bypasses the innate immune response and does not protect HCV from antiviral activity of interferon. Gastroenterology 2018; 154 (06) 1791.e22-1804.e22
    PubMedGoogle Scholar
  • 95 Konerman MA, Lok AS. Interferon treatment for hepatitis B. Clin Liver Dis 2016; 20 (04) 645-665
    CrossrefPubMedGoogle Scholar
  • 96 Rehermann B, Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology 2015; 61 (02) 712-721
    CrossrefPubMedGoogle Scholar
  • 97 Lucifora J, Xia Y, Reisinger F. , et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014; 343 (6176): 1221-1228
    CrossrefPubMedGoogle Scholar
  • 98 Ortega-Prieto AM, Dorner M. Immune evasion strategies during chronic hepatitis B and C virus infection. Vaccines (Basel) 2017; 5 (03) E24
    CrossrefPubMedGoogle Scholar
  • 99 Thomas DL, Thio CL, Martin MP. , et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461 (7265): 798-801
    PubMedGoogle Scholar
  • 100 Khan M, Syed GH, Kim SJ, Siddiqui A. Hepatitis B virus-induced Parkin-dependent recruitment of linear ubiquitin assembly complex (LUBAC) to mitochondria and attenuation of innate immunity. PLoS Pathog 2016; 12 (06) e1005693
    CrossrefPubMedGoogle Scholar
  • 101 Suslov A, Wieland S, Menne S. Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B. Curr Opin Virol 2018; 30: 9-17
    CrossrefPubMedGoogle Scholar
  • 102 Wang H, Ryu WS. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog 2010; 6 (07) e1000986
    CrossrefPubMedGoogle Scholar
  • 103 Morikawa K, Shimazaki T, Takeda R, Izumi T, Umumura M, Sakamoto N. Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection. Ann Transl Med 2016; 4 (18) 337
    CrossrefPubMedGoogle Scholar
  • 104 Lim KH, Park ES, Kim DH. , et al. Suppression of interferon-mediated anti-HBV response by single CpG methylation in the 5′-UTR of TRIM22. Gut 2018; 67 (01) 166-178
    CrossrefPubMedGoogle Scholar
  • 105 Wan Y, Cao W, Han T. , et al. Inducible Rubicon facilitates viral replication by antagonizing interferon production. Cell Mol Immunol 2017; 14 (07) 607-620
    PubMedGoogle Scholar
  • 106 Wentz MJ, Becker SA, Slagle BL. Dissociation of DDB1-binding and transactivation properties of the hepatitis B virus X protein. Virus Res 2000; 68 (01) 87-92
    CrossrefPubMedGoogle Scholar
  • 107 Murphy CM, Xu Y, Li F. , et al. Hepatitis B virus x protein promotes degradation of SMC5/6 to enhance HBV replication. Cell Reports 2016; 16 (11) 2846-2854
    CrossrefPubMedGoogle Scholar
  • 108 Decorsière A, Mueller H, van Breugel PC. , et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature 2016; 531 (7594): 386-389
    CrossrefPubMedGoogle Scholar
  • 109 Fernández M, Quiroga JA, Carreño V. Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins. J Gen Virol 2003; 84 (Pt 8): 2073-2082
    CrossrefPubMedGoogle Scholar
  • 110 Suslov A, Boldanova T, Wang X, Wieland S, Heim MH. Hepatitis B virus does not interfere with innate immune responses in the human liver. Gastroenterology 2018; 154 (06) 1778-1790
    CrossrefPubMedGoogle Scholar
  • 111 Lu HL, Liao F. Melanoma differentiation-associated gene 5 senses hepatitis B virus and activates innate immune signaling to suppress virus replication. J Immunol 2013; 191 (06) 3264-3276
    CrossrefPubMedGoogle Scholar
  • 112 Fletcher SP, Chin DJ, Ji Y. , et al. Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology 2012; 56 (03) 820-830
    CrossrefPubMedGoogle Scholar
  • 113 Barber GN. Cytoplasmic DNA innate immune pathways. Immunol Rev 2011; 243 (01) 99-108
    CrossrefPubMedGoogle Scholar
  • 114 Takeda K. Evolution and integration of innate immune recognition systems: the toll-like receptors. J Endotoxin Res 2005; 11 (01) 51-55
    CrossrefPubMedGoogle Scholar
  • 115 Kondo T, Kobayashi J, Saitoh T. , et al. DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. Proc Natl Acad Sci U S A 2013; 110 (08) 2969-2974
    CrossrefPubMedGoogle Scholar
  • 116 Du K, Liu J, Broering R. , et al. Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections. Expert Opin Drug Discov 2018; 13 (07) 661-670
    CrossrefPubMedGoogle Scholar